11月14日,在江苏苏州举行的2026创新药高质量发展大会上,国家医保局公布新增药品名单 1。信达生物自主研发的双靶点减重降糖原研药信尔美®(玛仕度肽注射液)以成人2型糖尿病适应症纳入国家医保药品目录 1。这是首个纳入该目录的中国双靶点减重降糖原研药,标志着国产创新药正式切入由外资主导的高景气GLP-1赛道 1。
该药物是全球首个且唯一获批的GCG/GLP-1双受体激动剂 1。回顾其上市历程,信尔美®于2025年6月获批超重/肥胖适应症,随后在2025年9月获批成人2型糖尿病适应症 1。此次入选打破了诺和诺德、礼来等跨国药企在GLP-1减重领域的技术和市场壁垒及单极格局 1。
During the 2026 Innovative Drug High-Quality Development Conference held in Suzhou, Jiangsu Province, on November 14, the National Healthcare Security Administration announced that Innovent Biologics’ self-developed dual-target weight-loss and glucose-lowering original drug, Xin'ermei® (Mazdutide Injection), has been included in the national medical insurance drug catalog 1. The inclusion was granted specifically for its indication in adult Type 2 diabetes, marking a significant milestone as this is the first Chinese dual-target original drug of this type to enter the catalog 1. This development signifies that domestic innovative drugs have officially entered the high-growth GLP-1 sector previously dominated by foreign companies, breaking the monopolar pattern held by multinational pharmaceutical firms 1.
Xin'ermei®, developed by Innovent Biologics, is recognized as the world’s first and only approved GCG/GLP-1 dual receptor agonist 1. The drug’s regulatory history includes its approval for overweight and obesity indications in June 2025, followed by its approval for adult Type 2 diabetes in September 2025 1. Its entry into the national insurance system represents a breakthrough against the technical and market barriers established by foreign brands such as Novo Nordisk and Eli Lilly in the GLP-1 weight loss field 1.
评论
还没有评论,欢迎留下第一条。